All In Biotech

Drug Trial Radar · NCT06875310

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 630 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

630

Planned (sponsor's estimate)

Start

Apr 24, 2025

Primary completion

Sep 7, 2029

Study completion Apr 30, 2032

Sponsor

Lead sponsor
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • AdagrasibDrug

    Specified dose on specified days

  • PembrolizumabDrug

    Specified dose on specified days

  • CarboplatinDrug

    Specified dose on specified days

  • PemetrexedDrug

    Specified dose on specified days

  • PlaceboDrug

    Specified dose on specified days

  • CisplatinDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) as Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded Independent Central Review (BICR)Time frame: Up to 7 years
  2. Overall Survival (OS)Time frame: Up to 7 years

Locations

317 sites in 35 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Highlands Oncology Group - Springdale

    Springdale, Arkansas · Recruiting

  • Providence Medical Foundation

    Fullerton, California · Recruiting

  • Local Institution - 0682

    Loma Linda, California · Not yet recruiting

  • Helios Clinical Research

    Long Beach, California · Recruiting

  • National Jewish Health Medical Center

    Denver, Colorado · Recruiting

  • Medical Oncology Hematology Consultants, PA

    Newark, Delaware · Recruiting

  • Morton Plant Hospital - BayCare Health System

    Clearwater, Florida · Recruiting

  • Cancer Specialists of North Florida

    Jacksonville, Florida · Recruiting

  • Local Institution - 0696

    Miami, Florida · Not yet recruiting

  • Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala

    Ocala, Florida · Recruiting

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida · Recruiting

  • Cancer Care Centers of Brevard, Inc.

    Palm Bay, Florida · Recruiting

  • Florida Clinical Trials Group.

    Plantation, Florida · Recruiting

  • St. Anthony's Hospital

    St. Petersburg, Florida · Recruiting

  • Florida Clinical Trials Group.

    Tamarac, Florida · Recruiting

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida · Recruiting

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital

    Marietta, Georgia · Recruiting

  • Illinois Cancer Specialists

    Arlington Heights, Illinois · Recruiting

  • University of Illinois at Chicago

    Chicago, Illinois · Recruiting

  • Springfield Clinic Main Campus

    Springfield, Illinois · Recruiting

  • Northwest Cancer Centers, P.C.

    Dyer, Indiana · Recruiting

  • Parkview Research Center at Parkview Regional Medical Center

    Fort Wayne, Indiana · Recruiting

  • Mercy Medical Center

    Cedar Rapids, Iowa · Recruiting

  • Saint Elizabeth Medical Center Edgewood

    Edgewood, Kentucky · Recruiting

  • The University of Louisville, James Graham Brown Cancer Center

    Louisville, Kentucky · Recruiting

  • Owensboro Medical Health System

    Owensboro, Kentucky · Recruiting

  • Mercy Health-Paducah Medical Oncology and Hematology

    Paducah, Kentucky · Recruiting

  • Louisiana State University Health Sciences Shreveport

    Shreveport, Louisiana · Recruiting

  • Velocity Clinical Research, Annapolis

    Annapolis, Maryland · Recruiting

  • Maryland Oncology Hematology - Columbia

    Columbia, Maryland · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • SSM Health Cancer Care - Fenton

    Fenton, Missouri · Recruiting

  • Local Institution - 0678

    Cooperstown, New York · Not yet recruiting

  • Ellis Hospital

    Schenectady, New York · Recruiting

  • White Plains Hospital

    White Plains, New York · Recruiting

  • WellSpan Oncology Research

    York, Pennsylvania · Recruiting

  • St Francis Cancer Center

    Greenville, South Carolina · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

Showing 40 of 317 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.